Correspondence 0001193125-23-164445 from OnKure Therapeutics, Inc. (OKUR) (CIK 0001637715) (OKUR)
OnKure Therapeutics, Inc. (OKUR) (CIK 0001637715)
Date: June 9, 2023 · CIK: 0001637715 · Accession: 0001193125-23-164445
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272421
Letter
Reneo Pharmaceuticals, Inc.
18575 Jamboree Road, Suite 275-S
Irvine, California 92612
(858) 283-0280
June 9, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Dillon Hagius
Re: Reneo Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-272421
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on June 13, 2023, or as soon thereafter as is practicable.
Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with Jason Kent of Cooley LLP, counsel to the registrant, at (212) 479-6044.
RENEO PHARMACEUTICALS, INC.
By:
/s/ Gregory J. Flesher
Gregory J. Flesher
President and Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm CORRESP Reneo Pharmaceuticals, Inc. 18575 Jamboree Road, Suite 275-S Irvine, California 92612 (858) 283-0280 June 9, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Dillon Hagius Re: Reneo Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-272421 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on June 13, 2023, or as soon thereafter as is practicable. Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with Jason Kent of Cooley LLP, counsel to the registrant, at (212) 479-6044. RENEO PHARMACEUTICALS, INC. By: /s/ Gregory J. Flesher Gregory J. Flesher President and Chief Executive Officer